Health
Clinical trial testing efficacy of antibody against SARS-CoV-2 begins – Medical Xpress
The University of Chicago Medicine is launching a clinical trial to examine the potential of an antibody against the SARS-CoV-2 spike protein for treating COVID-19, the disease caused by the novel coronavirus.
The University of Chicago Medicine is launching a clinical trial to examine the potential of an antibody against the SARS-CoV-2 spike protein for treating COVID-19, the disease caused by the novel coronavirus.
For the BLAZE-1 trial, UChicago is recruiting 22 participants to be treated with the LY-CoV555 antibody developed by Eli Lilly and Company in collaboration with AbCellera. The antibody was first identified by scientists at the National Institute of Allergy and Infectious Diseases and AbCe…
-
Noosa News20 hours agoWoman hospitalised with life-threatening facial burns
-
Noosa News22 hours agoMore than $25m in workers’ compensation claims relating to e-scooter and e-bike injuries made in Queensland over five-year period
-
Noosa News20 hours agoScenic Rim’s Summer Land farm aims to make camel meat, milk mainstream
-
Business20 hours agoWhy this broker just upgraded DroneShield shares